Artivion Inc offers cardiac and vascular surgeons a suite of aortic-centric solutions... Show more
The Moving Average Convergence Divergence (MACD) for AORT turned positive on June 23, 2025. Looking at past instances where AORT's MACD turned positive, the stock continued to rise in of 49 cases over the following month. The odds of a continued upward trend are .
The Momentum Indicator moved above the 0 level on June 16, 2025. You may want to consider a long position or call options on AORT as a result. In of 86 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .
The 50-day moving average for AORT moved above the 200-day moving average on June 24, 2025. This could be a long-term bullish signal for the stock as the stock shifts to an upward trend.
Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where AORT advanced for three days, in of 283 cases, the price rose further within the following month. The odds of a continued upward trend are .
The Aroon Indicator entered an Uptrend today. In of 250 cases where AORT Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .
The RSI Indicator has been in the overbought zone for 1 day. Expect a price pull-back in the near future.
The Stochastic Oscillator has been in the overbought zone for 2 days. Expect a price pull-back in the near future.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where AORT declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
AORT broke above its upper Bollinger Band on June 23, 2025. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. AORT’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (3.100) is normal, around the industry mean (24.307). AORT has a moderately high P/E Ratio (434.783) as compared to the industry average of (77.706). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (5.667). Dividend Yield (0.000) settles around the average of (0.018) among similar stocks. P/S Ratio (2.439) is also within normal values, averaging (42.612).
The Tickeron Seasonality Score of (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. AORT’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 90, placing this stock better than average.
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
a provider of cryopreserved human tissue for vascular transplant applications
Industry MedicalSpecialties
A.I.dvisor indicates that over the last year, AORT has been loosely correlated with SIBN. These tickers have moved in lockstep 47% of the time. This A.I.-generated data suggests there is some statistical probability that if AORT jumps, then SIBN could also see price increases.
Ticker / NAME | Correlation To AORT | 1D Price Change % | ||
---|---|---|---|---|
AORT | 100% | +0.84% | ||
SIBN - AORT | 47% Loosely correlated | +7.93% | ||
BSX - AORT | 45% Loosely correlated | +1.72% | ||
ITGR - AORT | 45% Loosely correlated | +1.13% | ||
TCMD - AORT | 43% Loosely correlated | +1.97% | ||
SONVY - AORT | 42% Loosely correlated | +1.71% | ||
More |